Update on the progestin-only contraception;Mise au point sur la contraception progestative

Journal de Gynecologie Obstetrique et Biologie de la Reproduction

Volumn 37, Issue 7, 2008, Pages 637-660

  Madelenat, P ^a,b   Koskas, M ^c  

^a Clinique de la Muette   (France)

^b Clinique Hartmann   (France)

^c BICHAT HOSPITAL   (France)

Author keywords

Bones; Breast; Breast feeding; Cardiovascular and metabolic risks; Contraindications; Efficacy; Indications; Mechanism of actions; Progestogen only contraception; Sides effects; Thromboembolic risks; Tolerance; Weight

Indexed keywords

ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ANTIRETROVIRUS AGENT; BRCA1 ASSOCIATED RING DOMAIN PROTEIN 1; BRCA2 PROTEIN; CARBAMAZEPINE; CHLORMADINONE ACETATE; CYPROTERONE ACETATE; DESOGESTREL; ETHOSUXIMIDE; ETONOGESTREL; GESTAGEN; GRISEOFULVIN; LEVONORGESTREL; LOPINAVIR; LYNESTRENOL; MEDROGESTONE; MEDROXYPROGESTERONE ACETATE; MEGESTROL ACETATE; NELFINAVIR; NEVIRAPINE; NORETHISTERONE; NORETHISTERONE ACETATE; ORAL CONTRACEPTIVE AGENT; PHENYTOIN; PRIMIDONE; RIFAMPICIN; RITONAVIR; UNINDEXED DRUG; ZIPEPROL;

BINDING AFFINITY; BONE DENSITY; BREAST CANCER; BREAST DISEASE; CANCER RISK; CATAMENIAL HEADACHE; CLINICAL PRACTICE; CONSENSUS; CONTRACEPTION; DRUG ANTAGONISM; DRUG BINDING; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; DYSPHORIA; ESTRADIOL BLOOD LEVEL; FRACTURE; FRANCE; HEADACHE; HUMAN; INTRAUTERINE CONTRACEPTIVE DEVICE; METABOLIC DISORDER; NONHUMAN; PREMENSTRUAL DYSPHORIA; PRESCRIPTION; PUERPERIUM; REVIEW; VALIDATION STUDY; VENOUS THROMBOEMBOLISM;

ADVISORY COMMITTEES; BONE DENSITY; BREAST; CARDIOVASCULAR DISEASES; CONTRACEPTIVES, ORAL, HORMONAL; DRUG INTERACTIONS; FEMALE; HUMANS; LIPID METABOLISM; PROGESTINS;

EID: 54249144329     PISSN: 03682315     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jgyn.2008.06.013     Document Type: Review

References (142)

1. Cheng C.V., and Boettcher B. Effects of steroids on the in vitro forward migration of human spermatozoa. Contraception 24 (1981) 183-194
2. Kühne D., Seidl S.T., and Göretzlehner G. Contraceptive treatment with chlormadinone and its effect on the endometrium: a histological investigation. Endokrinologie 59 (1972) 295-306
3. Kühne D., Göretzlehner G., and Seidl S.T. Contraception with low dose chlormadinone acetate: clinical and histological results. Acta Eur Fertil 2 (1970) 75-84
4. Sheppard B.L. Endometrial morphological changes in IUD users: a review. Contraception 36 (1987) 1-10
5. Jondet M., Letellier B., and Verdys M.T. Endometrial vascularization in Levonorgestrel intrauterine device users; computerized microvessel measurement sudy. Contraception 71 (2005) 60-64
6. Blacker C.S.J.M., Dubourg D., Denis-Rigaud C., and Fourtillan J.B. Action de la promegestone à la dose de 0,500 mg/j vingt jours par mois sur le pic ovulatoire de LH. Hormones, Reproduc, Metab 3 (1986) 277-282
7. Couzinet B., Young J., Kujas M., Meduri G., Brailly S., Thomas J.L., et al. The antigonadotropic activity of a 19-nor-progesterone derivative is exerted both at the hypothalamic and pituitary levels in women. J Clin Endocrinol Metab 84 (1999) 4191-4196
8. Rice C., Killick S., Hickling D., and Coelingh Bennink H. Ovarian activity and vaginal bleeding patterns with a desogestrel-only preparation at three different doses. Hum Reprod 11 (1996) 737-740
9. ®) after scheduled 1é-h delays in tablet intake. Contracepion 71 (2005) 8-13
10. Rice C.F., Killick S.R., Dieben T., and Coelingh Bennink H. A comparison of the inhibition of ovulation achieved by desogestrel 75 micrograms and levonorgestrel 30 micrograms daily. Hum Reprod 14 (1999) 982-985
11. Skouby S.O. The influence on the pituitary-ovarian function, cervical mucus and vaginal cytology of a new progestational compound. Contraception 14 (1976) 529-539
12. Pélissier C., Basdevant A., Conard J., Denis C., Caby J., Grimard A., et al. Administration prolongée d'acétate de Chlormadinone. Effets métaboliques, tensionnels et hormonaux. Gynécologie 42 (1991) 79-86
13. Chassard D., and Schatz B. Activité antigonadotrope de l'acétate de chlormadinone chez la femme en période d'activité génitale. Gynecol Obstet Fertil 33 (2005) 29-34
14. Jamin C., Batallan A., and Madelenat P. Propriétés antigonadotropes d'un progestatif norprégnane : l'exemple du nomégestrol acétate. Gynecol Obstet Fertil 31 (2003) 70-81
15. Grimes D.A., Lopez L.M., Manion C., and Schulz K.F. Cochrane systematic reviews of IUD trials: lessons learned. Contraception 75 (2007) S55-S59
16. French R, Van Vliet H, Cowan F et al. Hormonally impregnated intrauterine systemes (IUSs) versus other forms of reversible contraceptives as effective methods of preventing pregnancy. CD001776.
17. Thonneau P.F., Almont T., de la Rochebrochard E., and Maria B. Risk factors for IUD failure: results of a large multicentre case-control study. Hum Reprod 21 (2006) 2612-2616
18. Thonneau P.F., and Almont T.E. Contraceptive efficacy of intrauterine devices. javascript:AL_get(this, 'jour', 'Am J Obstet Gynecol.'). Am J Obstet Gynecol 198 (2008) 248-253 Epub 2008 Jan 25
19. ACOG practice bulletin. No. 73: use of hormonal contraception in women with coexisting medical conditions. Obstet Gynecol 2006; 107: 1453-72.
20. Crawford P. Interactions between antiepileptic drugs and hormonal contraception. CNS Drugs 16 (2002) 263-272
21. British Medical Association and the Royal Pharmaceutical Society of Great Britain. British National Formulary-BNF40, September 2000.
22. Kuhl H., Jung-Hoffmann C., Storch A., Fitzner M., and Rühl E. New aspects on the mechanism of action of contraceptive steroids: recent pharmacokinetic studies of low dose formulations. Adv Contracept (1991) 149-163
23. Clinical pharmacokinetics of contraceptive steroids. An update.Shenfield GM, Griffin JM. Clin Pharmacokinet 1991 20: 15-37.
24. Krauss G.L., Brandt J., Campbell M., Plate C., and Summerfield M. Antiepileptic medication and oral contraceptive interactions: a national survey of neurologists and obstetricians. Neurology 46 (1996) 1534-1539
25. Weaver K., and Glasier A. Interaction between broad-spectrum antibiotics and the combined oral contraceptive pill. A literature review. Contraception 59 (1999) 71-78
26. Levy M.J., Smotrich D.B., Widra E.A., Sagoskin A.W., Murray D.L., and Hall J.L. The predictive value of serum progesterone and 17-OH progesterone levels on in vitro fertilization outcome. J Assist Reprod Genet 12 (1995) 161-166
27. Matiluko A.A., Soundarajan L., and Hogston P. Early contraceptive failure of Implanon in an HIV-seropositive patient on triple antiretroviral therapy with zidovudine, lamivudine and efavirenz. J Fam Plann Reprod Health Care 33 (2007) 277-278
28. Greendale G.A., Palla S.L., Ursin G., Laughlin G.A., Crandall C., Pike M.C., et al. The association of endogenous sex steroids and sex steroid binding proteins with mammographic density: results from the Postmenopausal Estrogen/Progestin Interventions Mammographic Density Study. Am J Epidemiol 162 (2005) 826-834
29. Dennerstein L., Spencer-Gardner C., Gotts G., Brown J.B., Smith M.A., and Burrows G.D. Progesterone and the premenstrual syndrome: a double blind crossover trial. Br Med J (Clin Res Ed) 290 (1985) 1617-1621
30. Pye J.K., Mansel R.E., and Hughes L.E. Clinical experience of drug treatments for mastalgia. Lancet 2 (1985) 373-377
31. Colin C., Gaspard U., and Lambotte R. Relationship of mastodynia with its endocrine environment and treatment in a double blind trial with lynestrenol. Arch Gynakol 225 (1978) 7-13
32. Maddox P.R., Harrison B.J., Horobin J.M., Walker K., Mansel R.E., Preece P.E., et al. A randomised controlled trial of medroxyprogesterone acetate in mastalgia. Ann R Coll Surg Engl 72 (1990) 71-76
33. o 1.
34. Euhus D.M., and Uyehara C. Influence of parenteral progesterones on the prevalence and severity of mastalgia in premenopausal women: a multi-institutional cross-sectional study. J Am Coll Surg 184 (1997) 596-604
35. Pons J.Y., Bernard A.M., and Thomas J.L. L'acétate de nomégestrol dans le traitement des mastopathies bénignes. Résultats d'un essai contrôlé. Le Sein 6 (1996) 19-23
36. Plu-Bureau G, Thalabard JC. Les progestatifs en cancérologie mammaire. Progestatifs et cancer du sein : données épidémiologiques. 28es journées de la SFSPM. Lille, novembre 2006.
37. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies. Lancet 1996; 347: 1713-27.
38. Dumeaux V., Alsaker E., and Lund E. Breast cancer and specific types of oral contraceptives: a large Norwegian cohort study. Int J Cancer 105 (2003) 844-850
39. Kumle M., Weiderpass E., Braaten T., Persson I., Adami H.O., and Lund E. Use of oral contraceptives and breast cancer risk: the Norwegian-Swedish Women's Lifestyle and Health Cohort Study. Cancer Epidemiol Biomarkers Prev 11 (2002) 1375-1381
40. Plu-Bureau G., Le M.G., Thalabard J.C., Sitruk-Ware R., and Mauvais-Jarvis P. Percutaneous progesterone use and risk of breast cancer: results from a French cohort study of premenopausal women with benign breast disease. Cancer Detect Prev 23 (1999) 290-296
41. Plu-Bureau G., Le M.G., Sitruk-Ware R., Thalabard J.C., and Mauvais-Jarvis P. Progestogen use and decreased risk of breast cancer in a cohort study of premenopausal women with benign breast disease. Br J Cancer 70 (1994) 270-277
42. Fabre A., Fournier A., Mesrine S., Desreux J., Gompel A., Boutron-Ruault M.C., et al. Oral progestagens before menopause and breast cancer risk. Br J Cancer 96 (2007) 841-844
43. Shapiro S., Rosenberg L., Hoffman M., Truter H., Cooper D., Rao S., et al. Risk of breast cancer in relation to the use of injectable progestogen contraceptives and combined estrogen/progestogen contraceptives. Am J Epidemiol 151 (2000) 396-403
44. Strom B.L., Berlin J.A., Weber A.L., Norman S.A., Bernstein L., Burkman R.T., et al. Absence of an effect of injectable and implantable progestin-only contraceptives on subsequent risk of breast cancer. Contraception 69 (2004) 353-360
45. Meirik O., Farley T.M., Sivin I., and Diaz S. Post-marketing surveillance of Norplant contraceptive implants: I. Contraceptive efficacy and reproductive health. International Collaborative Post Marketing Surveillance. Contraception 63 (2001) 167-186
46. Backman T., Rauramo I., Jaakkola K., Inki P., Vaahtera K., Launonen A., et al. Use of the levonorgestrel-releasing intrauterine system and breast cancer. Obstet Gynecol 106 (2005) 813-817
47. Stanford J.L., Brinton L.A., and Hoover R.N. Oral contraceptives and breast cancer: results from an expanded case-control study. Br J Cancer 60 (1989) 375-381
48. Oral contraceptives and breast cancer. IPPF Med Bull 1989; 23: 3.
49. Eisinger F., Bressac B., Castaigne D., Cottu P.H., Lansac J., Lefranc J.P., et al. Identification et prise en charge des prédispositions héréditaires aux cancers du sein et de l'ovaire (mise à jour 2004). Bull Cancer 91 (2004) 219-237
50. Brohet R.M., Goldgar D.E., Easton D.F., Antoniou A.C., Andrieu N., Chang-Claude J., et al. Oral Contraceptives and Breast Cancer Risk in the International BRCA1/2 Carrier Cohort Study: A Report from EMBRACE, GENEPSO, GEO-HEBON, and the IBCCS Collaborating Group. J Clin Oncol 25 (2007) 3831-3836
51. Collaborative Group on Epidemiological Studies of Ovarian Cancer. Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23257 women with ovarian cancer and 87303 controls. Lancet 2008; 371: 303-14.
52. Narod S.A., Risch H., Moslehi R., Dørum A., Neuhausen S., Olsson H., et al. Oral contraceptives and the risk of hereditary ovarian cancer. Hereditary Ovarian Cancer Clinical Study Group. N Engl J Med 339 (1998) 424-428
53. Lappe J.M., Stegman M.R., and Recker R.R. The impact of lifestyle factors on stress fractures in female Army recruits. Osteoporos Int 12 (2001) 35-42
54. Beerthuizen R., van Beek A., Massai R., Makarainen L., Hout J., and Bennink H.C. Bone mineral density during long-term use of the progestagen contraceptive implant Implanon compared to a non-hormonal method of contraception. Hum Reprod 15 (2000) 118-122
55. Curtis K.M., and Martins S.L. Progestogen-only contraception and bone mineral density: a systematic review. Contraception 73 (2006) 470-487
56. Banks E., Berrington A., and Casabonne D. Overview of the relationship between use of progestogen-only contraceptives and bone mineral density. BJOG 108 (2001) 1214-1221
57. Berenson A.B., Breitkopf C.R., Grady J.J., Rickert V.I., and Thomas A. Effects of hormonal contraception on bone mineral density after 24 months of use. Obstet Gynecol 103 (2004) 899-906
58. Clark M.K., Sowers M.R., Nichols S., and Levy B. Bone mineral density changes over two years in first-time users of depot medroxyprogesterone acetate. Fertil Steril 82 (2004) 1580-1586
59. Cundy T., Cornish J., Evans M.C., Roberts H., and Reid I.R. Recovery of bone density in women who stop using medroxyprogesterone acetate. BMJ 308 (1994) 247-248
60. Cundy T., and Reid I. Depot medroxyprogesterone and bone density. BMJ 308 (1994) 1567-1568
61. Cromer B.A., Stager M., Bonny A., Lazebnik R., Rome E., Ziegler J., et al. Depot medroxyprogesterone acetate, oral contraceptives and bone mineral density in a cohort of adolescent girls. J Adolesc Health 35 (2004) 434-441
62. Cromer B.A., Scholes D., Berenson A., Cundy T., Clark M.K., and Kaunitz A.M. Depot medroxyprogesterone acetate and bone mineral density in adolescents-the Black Box Warning: a Position Paper of the Society for Adolescent Medicine. J Adolesc Health 39 (2006) 296-301
63. Naessen T., Olsson S.E., and Gudmundson J. Differential effects on bone density of progestogen-only methods for contraception in premenopausal women. Contraception 52 (1995) 35-39
64. Bahamondes L., Monteiro-Dantas C., Espejo-Arce X., Dos Santos Fernandes A.M., Lui-Filho J.F., Perrotti M., et al. A prospective study of the forearm bone density of users of etonorgestrel- and levonorgestrel-releasing contraceptive implants. Hum Reprod 21 (2006) 466-470
65. Zartarian M., Chevallier T., Micheletti M.C., Leber C., and Jamin C. Tolérance biologique et clinique du Nomégestrol acétate, administé seul puis associé en séquentiel inversé au 17β estradiol cutané, chez des femmes à risque présentant une dyslipoprotéinémie de type II a. Annales d'Endocrinologie 59 (1998) 411-416
66. Pelissier C., Basdevant A., Conard J., Egloff M., Husson T., and Guyenne T.T. Contraception progestative par l'acétate de chlormadinone chez les femmes à risques vasculaires. Contracept Fertil Sex (Paris) 15 (1987) 45-54
67. Kuhl H. Effects of progestogens on haemostasis. Maturitas 24 (1996) 1-19
68. Odlind V., Milsom I., Persson I., and Victor A. Can changes in sex hormone binding globulin predict the risk of venous thromboembolism with combined oral contraceptive pills?. Acta Obstet Gynecol Scand 81 (2002) 482-490
69. Pakarinen P., Lähteenmäki P., and Rutanen E.M. The effect of intrauterine and oral levonorgestrel administration on serum concentrations of sex hormone-binding globulin, insulin and insulin-like growth factor binding protein-1. Acta Obstet Gynecol Scand 78 (1999) 423-428
70. Alhenc-Gelas M., Plu-Bureau G., Guillonneau S., Kirzin J.M., Aiach M., Ochat N., et al. Impact of progestogens on actived protein (APC) resistance among users of oral contraceptives. J Thromb Haemost 2 (2004) 1594-1600
71. Kemmeren J.M., Algra A., Meijers J.C., Bouma B.N., and Grobbee D.E. Effect of second- and third-generation oral contraceptives and their respective progestagens on the coagulation system in the absence or presence of the factor V Leiden mutation. Thromb Haemost 87 (2002) 199-205
72. Winkler U.H., Howie H., Buhler K., Korver T., Geurts T.B., and Coelingh Bennink H.J. A randomized controlled double-blind study of the effects on hemostasis of two progestogen-only pills containing 75 microgram desogestrel or 30 microgram levonorgestrel. Contraception 57 (1998) 385-392
73. Conard J., Samama M., Horellou M.N., Zorn J.R., and Neau C. Antithrombin III and oral contraception with progestagen-only preparation. Lancet 2 (1979) 471
74. Bounameaux H., Duckert F., Walter M., and Bounameaux Y. The determination of antithrombin III. Comparison of six methods. Effect of oral contraceptive therapy. Thromb Haemost 39 (1978) 607-615
75. Barbosa I., Coutinho E., Athayde C., Ladipo O., Olsson S.E., and Ulmsten U. The effects of nomegestrol acetate subdermal implant (Uniplant) on carbohydrate metabolism, serum lipoproteins and on hepatic function in women. Contraception 52 (1995) 111-114
76. Vieira C.S., Ferriani R.A., Garcia A.A., Pintao M.C., Azevedo G.D., Gomes M.K., et al. Use of the etonogestrel-releasing implant is associated with hypoactivation of the coagulation cascade. Hum Reprod 22 (2007) 2196-2201
77. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Cardiovascular disease and use of oral and injectable progestogen-only contraceptives and combined injectable contraceptives. Results of an international, multicenter, case-control study. Contraception 1998; 57: 315-24.
78. Heinemann L.A., Assmann A., Dominh T., and Garbe E. Oral progestogen-only contraceptives and cardiovascular risk: results from the Transnational Study on Oral Contraceptives and the Health of Young Women. Eur J Contracept Reprod Health Care 4 (1999) 67-73
79. Canonico M., Oger E., Plu-Bureau G., Conard J., Meyer G., Lévesque H., et al. Estrogen and Thromboembolism Risk (ESTHER) Study Group. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation 115 (2007) 840-845
80. August P., and Oparil S. Hypertension in women. J Clin Endocrinol Metab 84 (1999) 1862-1866
81. Khaw K.T., and Peart W.S. Blood pressure and contraceptive use. Br Med J (Clin Res Ed) 285 (1982) 403-407
82. Millet D., Keledjian P., Corvol P., Milliez P., and Menard J. Contraception par la progesterone en continu chez les femmes hypertendues. Gynécologie 30 (1979) 531-536
83. Spellacy W.N., and Birk S.A. The effect of intrauterine devices, oral contraceptives, estrogens, and progestogens on blood pressure. Am J Obstet Gynecol 112 (1972) 912-919
84. Oelkers W., Schoneshofer M., and Blumel A. Effects of progesterone and four synthetic progestagens on sodium balance and the renin-aldosterone system in man. J Clin Endocrinol Metab 39 (1974) 882-890
85. Conard J., Plu-Bureau G., Bahi N., Horellou M.H., Pelissier C., and Thalabard J.C. Progestogen-only contraception in women at high risk of venous thromboembolism. Contraception 70 (2004) 437-441
86. Rosendaal F.R. Venous thrombosis: a multicausal disease. Lancet 353 (1999) 1167-1173
87. Gompel A., Pelissier C., Kuttenn F., and Mauvais-Jarvis P. Hormones et lupus. Rev Med Intern 6 (1985) 543-552
88. Sanchez-Guerrero J., Uribe A.G., Jimenez-Santana L., Mestanza-Peralta M., Lara-Reyes P., Seuc A.H., et al. A trial of contraceptive methods in women with systemic lupus erythematosus. N Engl J Med 353 (2005) 2539-2549
89. Tincani A., Nuzzo M., Lojacono A., Cattalini M., and Meini A. Contraception in adolescents with systemic lupus erythematosus. Lupus 16 (2007) 600-605
90. Jungers P., Dougados W., and Pélissier C. Influence of oral contraceptive therapy on the activity of systemic lupus erythematosus. Arthritis Rheum 25 (1982) 618-623
91. Sherif K. Benefits and risks of oral contraceptives. Am J Obstet Gynecol 180 (1999) S343-S348
92. Kemmeren J.M., Algra A., Meijers J.C., Tans G., Bouma B.N., Curvers J., et al. Effect of second- and third-generation oral contraceptives on the protein C system in the absence or presence of the factor V Leiden mutation: a randomized trial. Blood 103 (2004) 927-933
93. Faddah L.M., Al-Rehany M.A., Abdel-Hamid N.M., and Bakeet A.A. Oxidative stress, lipid profile and liver functions in average egyptian long term depo medroxy progesterone acetate (DMPA) users. Molecules 10 (2005) 1145-1152
94. Westhoff C. Depot medroxyprogesterone acetate contraception. Metabolic parameters and mood changes. J Reprod Med 41 (1996) 401-406
95. Collins D. Selectivity information on desogestrel. Am J Obstet Gynecol 168 (1993) 1010-1016
96. Merki-Feld G.S., Imthurn B., and Seifert B. Effects of the progestagen-only contraceptive implant Implanon(R) on cardiovascular risk factors. Clin Endocrinol (Oxf) 68 (2008) 355-360 Epub 2007 Sept 14
97. Lopez L.M., Grimes D.A., and Schulz K.F. Steroidal contraceptives: effect on carbohydrate metabolism in women without diabetes mellitus. Cochrane Database Syst Rev (2007) CD006133
98. Ball M.J., Ashwell E., and Gillmer M.D. Progestagen-only oral contraceptives: comparison of the metabolic effects of levonorgestrel and norethisterone. Contraception 44 (1991) 223-233
99. Ronnerdag M., and Odlind V. Health effects of long-term use of the intrauterine levonorgestrel-releasing system. A follow-up study over 12 years of continuous use. Acta Obstet Gynecol Scand 78 (1999) 716-721
100. Nilsson C.G., Allonen H., Diaz J., and Luukkainen T. Two years' experience with two levonorgestrel-releasing intrauterine devices and one copper-releasing intrauterine device: a randomized comparative performance study. Fertil Steril 39 (1983) 187-192
101. Zheng S.R., Zheng H.M., Qian S.Z., Sang G.W., and Kaper R.F. A randomized multicenter study comparing the efficacy and bleeding pattern of a single-rod (Implanon) and a six-capsule (Norplant) hormonal contraceptive implant. Contraception 60 (1999) 1-8
102. Kivela A., Ruuskanen M., Agren U., and Dieben T. The effects of two progrestogen-only pills containing either desogestrel (75 microgram/day) or levonorgestrel (30 microgram/day) on carbohydrate metabolism and adrenal and thyroid function. Eur J Contracept Reprod Health Care 6 (2001) 71-77
103. e Edn. (2007), Masson, Paris 397-404
104. Urbancsek J. An integrated analysis of nonmenstrual adverse events with Implanon. Contraception 58 (1998) 109S-115S
105. ®): results from 11 international clinical trials. Fertility and Sterility 2008: "in press".
106. Durand J.L., and Bressler R. Clinical pharmacology of the steroidal oral contraceptives. Adv Intern Med 24 (1979) 97-126
107. Jiménez M.F., Arbo E., Vetori D., de Freitas F.M., and Cunha-Filho J.S. The effect of the levonorgestrel-releasing intrauterine system and the copper intrauterine device on subendometrial microvascularization and uterine artery blood flow. Fertil Steril (2008)
108. Alvarez F., Brache V., Faundes A., Tejada A.S., and Thevenin F. Ultrasonographic and endocrine evaluation of ovarian function among Norplant implants users with regular menses. Contraception 54 (1996) 275-279
109. ESHRE Capri Workshop Group. Ovarian and endometrial function during hormonal contraception. Hum Reprod 2001; 16: 1527-35.
110. Raudrant D., and Rabe T. Progestogens with antiandrogenic properties. Drugs 63 (2003) 463-492
111. Paul C., Skegg D.C., and Williams S. Depot medroxyprogesterone acetate. Patterns of use and reasons for discontinuation. Contraception 56 (1997) 209-214
112. Li R.H., Lo S.S., Teh D.K., Tong N.C., Tsui M.H., Cheung K.B., et al. Impact of common contraceptive methods on quality of life and sexual function in Hong Kong Chinese women. Contraception 70 (2004) 474-482
113. Graham C.A., Ramos R., Bancroft J., Maglaya C., and Farley T.M. The effects of steroidal contraceptives on the well-being and sexuality of women: a double-blind, placebo-controlled, two-centre study of combined and progestogen-only methods. Contraception 52 (1995) 363-369
114. Brache V., Faundes A., and Alvarez F. Risk-benefit effects of implantable contraceptives in women. Expert Opin Drug Saf 2 (2003) 321-332
115. Zartarian M., Micheletti M.C., Gauthier A., Torres C., and Dewailly D. Effects of nomegestrol acetate administered alone or with cutaneous 17 beta estradiol in inversed sequence on cycle quality and hot flashes in periomenopausal women. Contracept Fertil Sex 26 (1998) 69-76
116. Britton C., McCormick F.M., Renfrew M.J., Wade A., and King S.E. Support for breastfeeding mothers. Cochrane Database Syst Rev (2007) CD001141
117. Bjarnadóttir R.I., Gottfredsdóttir H., Sigurdardóttir K., Geirsson R.T., and Dieben T.O. Comparative study of the effects of a progestogen-only pill containing desogestrel and an intra uterine contraceptive device in lactating women. Br J Obstet Gynaecol 108 (2001) 1174-1180
118. Grimes D., Schulz K., and Stanwood N. Immediate postabortal insertion of intrauterine devices. Cochrane Database Syst Rev (2004) CD001777. Review
119. Wahab M., and Al-Azzawi F. Meningioma and hormonal influences. Climacteric 6 (2003) 285-292
120. WHO. Medical Eligibility Criteria for Contraceptive Use. 3eme edition, WHO 2004.
121. Al-Jefout M., Palmer J., and Fraser I.S. Simultaneous use of a levonorgestrel intrauterine system and an etonogestrel subdermal implant for debilitating adolescent endometriosis. Aust N Z J Obstet Gynaecol 47 (2007) 247-249
122. Yisa S.B., Okenwa A.A., and Husemeyer R.P. Treatment of pelvic endometriosis with etonogestrel subdermal implant (Implanon). J Fam Plann Reprod Health Care 31 (2005) 67-70
123. Fedele L., Bianchi S., Zanconato G., Portuese A., and Raffaelli R. Use of a levonorgestrel-releasing intrauterine device in the treatment of rectovaginal endometriosis. Fertil Steril 75 (2001) 485-488
124. Vercellini P., Aimi G., Panazza S., De Giorgi O., Pesole A., and Crosignani P.G. A levonorgestrel-releasing intrauterine system for the treatment of dysmenorrhea associated with endometriosis: a pilot study. Fertil Steril 72 (1999) 505-508
125. Lockhat F.B., Emembolu J.O., and Konje J.C. The efficacy, side-effects and continuation rates in women with symptomatic endometriosis undergoing treatment with an intra-uterine administered progestogen (levonorgestrel): a 3-year follow-up. Hum Reprod 20 (2005) 789-793
126. Afssaps. Recommendations of good practice: drug therapy for fibroma of uterus. Gynecol Obstet Fertil 2005; 33(7-8): 547-52.
127. Bahamondes L., Petta C.A., Fernandes A., and Monteiro I. Use of the levonorgestrel-releasing intrauterine system in women with endometriosis, chronic pelvic pain and dysmenorrhea. Contraception 75 (2007) S134-S139
128. Fedele L., Bianchi S., Raffaelli R., Portuese A., and Dorta M. Treatment of adenomyosis-associated menorrhagia with a levonorgestrel-releasing intrauterine device. Fertil Steril 68 (1997) 426-429
129. Fong Y.F., and Singh K. Effect of the levonorgestrel-releasing intrauterine system on uterine myomas in a renal transplant patient. Contraception 60 (1999) 51-53
130. He S.M., Wei M.X., Han Y.H., and He L.H. Effect of levonorgestrel-releasing intrauterine system in the treatment of adenomyosis. Zhonghua Fu Chan Ke Za Zhi 40 (2005) 536-538
131. Cho S., Nam A., Kim H., Chay D., Park K., Cho D.J., et al. Clinical effects of the levonorgestrel-releasing intrauterine device in patients with adenomyosis. Am J Obstet Gynecol (2008)
132. Chan S.S., Tam W.H., Yeo W., Yu M.M., Ng D.P., Wong A.W., et al. A randomised controlled trial of prophylactic levonorgestrel intrauterine system in tamoxifen-treated women. BJOG 114 (2007) 1510-1515
133. Neven P. Local levonorgestrel to prevent tamoxifen-related endometrial lesions. Lancet 356 (2000) 1698-1699
134. Lamberts S.W., Tanghe H.L., Avezaat C.J., Braakman R., Wijngaarde R., Koper J.W., et al. Mifepristone (RU 486) treatment of meningiomas. J Neurol Neurosurg Psychiatry 55 (1992) 486-490
135. Custer B., Longstreth Jr. W.T., Phillips L.E., Koepsell T.D., and Van Belle G. Hormonal exposures and the risk of intracranial meningioma in women: a population-based case-control study. BMC Cancer 6 (2006) 152
136. Gruber T., Dare A.O., Balos L.L., Lele S., and Fenstermaker R.A. Multiple meningiomas arising during long-term therapy with the progesterone agonist megestrol acetate. Case report. J Neurosurg 100 (2004) 328-331
137. Rabe T., Feldmann K., Heinemann L., and Runnebaum B. Cyproterone acetate: is it hepato- or genotoxic?. Drug Saf 14 (1996) 25-38
138. Fernandez H., Coste J., Job-Spira N., Spira A., and Papiernik E. Facteurs de risque de la grossesse extra-utérine: étude cas témoins dans 7 maternités de la région parisienne. J Gynecol Obstet Biol Reprod 20 (1991) 373-379
139. Backman T., Rauramo I., Huhtala S., and Koskenvuo M. Pregnancy during the use of levonorgestrel intrauterine system. Am J Obstet Gynecol 190 (2004) 50-54
140. ®: difficultés d'insertion et de retrait, échecs contraceptifs. Gynecol Obstet Fertil 33 (2005) 986-990
141. World Health Organization Collaborative Study of Cardiovascular and Steroid Hormone Contraception. A multinational case-control study of cardiovascular disease and steroid hormone contraceptives. Description and validation of methods. J Clin Epidemiol 1995; 48: 1513-47.
142. Sitruk-Ware R. Pharmacological profile of progestins. Maturitas 47 (2004) 277-283